Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Anika Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.83
Shares Outstanding14.8M
Average Volume (10 days)57.1K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($5.06)
Sales (TTM)$11.26
Book Value (MRQ)$14.22
Cash Flow (TTM)$0.60
Cash (MRQ)$6.51

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy1
 
Buy0
 
Hold0
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Anne Nunes
SVP, Chief Operations Officer
(732)
Dispose
Oct 1, 2024
Richard Stephen
Director
5,771
Acquire
Jul 9, 2024
Larsen Glenn
Director
5,771
Acquire
Jul 9, 2024
Jellison William
5,771
Acquire
Jul 9, 2024
Capper Joseph H.
5,771
Acquire
Jul 9, 2024

Recent SEC Filings

Insider Buy/Sell
Oct 4, 2024
Quarterly Financials
Aug 8, 2024
Company Events
Aug 8, 2024
Insider Buy/Sell
Jul 11, 2024
Insider Buy/Sell
Jul 11, 2024
To Top